心脏医生手机应用程序对心力衰竭知识和药物坚持的影响:试点随机对照试验
Victor Buswell1, Emmanuelle Massie2, Elena Tessitore2
1Faculty of Medicine, University of Geneva, Geneva, Switzerland.
JMIR cardio
|February 23, 2026
概括
在30天的研究中,Cardio-Meds移动应用程序改善了患者的心力衰竭 (HF) 的知识,但没有影响药物坚持. 该应用程序展示了高可用性和患者接受度.
科学领域:
- 心脏病学 心脏病学
- 数字健康数字健康
- 患者自我管理
背景情况:
- 心力衰竭 (HF) 管理需要患者的理解和坚持,这往往是具有挑战性的.
- 现有的HF移动健康应用程序可能缺乏验证的内容和本地相关性.
- Cardio-Meds是一个移动应用程序,旨在通过教育,提醒和监控工具来增强HF自我管理.
研究的目的:
- 评估心脏医生手机应用程序干预对高频知识和药物坚持的影响.
- 评估心脏医生应用程序在HF患者中减少或轻微减少射出分数的可用性和可接受性.
主要方法:
- 一个单中心,试点随机对照试验与49名参与者进行.
- 参与者使用了30天的 Cardio-Meds 应用程序或作为对照组.
- 结果包括HF知识 (DHFKS) 和药物坚持,通过标准化问卷进行评估.
主要成果:
- 与对照组相比,心脏-医疗小组的HF知识在短期内显著增加.
- 在30天内,两组之间没有观察到药物坚持的显著差异.
- 该应用程序展示了高的可用性 (平均得分84.3) 和可接受性,64%的用户打算继续使用.
结论:
- 心脏-医疗干预有效地改善了30天内稳定的门诊患者的HF知识.
- 该应用程序对患者来说是可用的和可接受的,但在这个短期试验中没有影响药物坚持.
- 需要进一步的多中心研究和更长的随访,以确定心脏-Meds.的临床影响.
相关概念视频
01:30Heart Failure V: Medical Management
400
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
400
01:29Cardiomyopathy V: Interprofessional Care
520
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
520
01:22Heart Failure VI: Adjunct Therapies
442
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
442
01:22Heart Failure Drugs: β-Blockers
1.0K
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
1.0K
01:26Heart Failure Drugs: Inotropic Agents
1.6K
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
1.6K
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
1.3K
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.3K